| Company/Division name | Alcon |
| Parent company | Novartis |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2023 |
| Year reshoring implemented or to be implemented: | 2028 |
| Offshore, work was done: | In-house |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 153 |
| Country(ies) from which reshored: | Switzerland |
| City reshored to: | Forth Worth |
| State(s) reshored to: | TX |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals, Medical Equipment & Supplies |
| Product(s) reshored | eye car products |
| What domestic positive factors made reshoring more attractive? | Government Incentives, Applied to Texas Enterprise Zone Program |
| Government Incentive dollar amount: | $1.25M if accepted |
